Chengdu Hanpharm Pharmaceutical

Chengdu Hanpharm Pharmaceutical, a subsidiary of China Grand Pharmaceutical and Healthcare Holdings, is a specialized pharmaceutical enterprise based in Chengdu, China. The company focuses on the research, development, and production of biochemical and chemical drugs, with a particular emphasis on critical care and immunology. Its flagship product, Ulinastatin (marketed as Hanpulin), is a widely recognized treatment for acute pancreatitis and systemic inflammatory response syndrome. Hanpharm's portfolio also includes immunomodulators like Thymopentin and cardiovascular treatments such as Alprostadil, all manufactured in GMP-certified facilities. As part of the Grand Pharma group, the company leverages extensive distribution networks to supply essential medications across the Chinese healthcare system.